Since accumulation of excess TGs can lead to the pathogenesis of multiple metabolic disorders, such as obesity, type II diabetes, and fatty liver disease, DGAT1 and DGAT2 have been considered potential targets for the treatment of metabolic diseases [152]. This evidence concerns the gene DGAT1 and Other metabolic disease.